ANI Pharmaceuticals (NASDAQ:ANIP) Issues FY 2025 Earnings Guidance

ANI Pharmaceuticals (NASDAQ:ANIP) issued an update on its FY 2025 earnings guidance on Tuesday morning. The company provided EPS guidance of 6.120-6.490 for the period, compared to the consensus EPS estimate of 5.560. The company issued revenue guidance of $756.0 million-$776.0 million, compared to the consensus revenue estimate of $724.9 million.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on ANIP shares. HC Wainwright reaffirmed a “buy” rating and set a $94.00 target price on shares of ANI Pharmaceuticals in a research note on Monday. StockNews.com lowered ANI Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Monday. Leerink Partnrs upgraded ANI Pharmaceuticals to a “strong-buy” rating in a research report on Wednesday, December 11th. Finally, Leerink Partners started coverage on shares of ANI Pharmaceuticals in a report on Wednesday, December 11th. They issued an “outperform” rating and a $80.00 price target on the stock. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, six have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, ANI Pharmaceuticals has an average rating of “Moderate Buy” and an average price target of $77.71.

ANI Pharmaceuticals Stock Up 1.1 %

NASDAQ:ANIP opened at $59.13 on Wednesday. The company has a debt-to-equity ratio of 1.52, a current ratio of 2.74 and a quick ratio of 1.97. ANI Pharmaceuticals has a 1-year low of $52.50 and a 1-year high of $70.81. The company has a 50-day moving average of $57.32 and a 200 day moving average of $58.11. The firm has a market cap of $1.24 billion, a PE ratio of -107.51 and a beta of 0.74.

Insider Transactions at ANI Pharmaceuticals

In other ANI Pharmaceuticals news, CFO Stephen P. Carey sold 7,500 shares of ANI Pharmaceuticals stock in a transaction on Tuesday, December 17th. The shares were sold at an average price of $55.79, for a total value of $418,425.00. Following the transaction, the chief financial officer now directly owns 154,468 shares of the company’s stock, valued at approximately $8,617,769.72. The trade was a 4.63 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Krista Davis sold 1,000 shares of the company’s stock in a transaction dated Wednesday, December 11th. The shares were sold at an average price of $60.00, for a total value of $60,000.00. Following the transaction, the senior vice president now directly owns 49,059 shares in the company, valued at $2,943,540. This represents a 2.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 10,300 shares of company stock valued at $584,009. Company insiders own 12.70% of the company’s stock.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.